Non-small cell lung cancer is the most prevalent form of lung cancer and accounts for more than 80% of all lung cancer cases. Circulating tumor cells (CTCs) lead to metastases and often…
Tag: Lung Cancer News
FDA Approves Libtayo as Monotherapy for Advanced NSCLC
Lung cancer is one of the leading causes of cancer-related deaths worldwide. In the year 2020, an estimated 225,000 new cases were diagnosed in the United States. Also, approximately 84% of all…
Lung Cancer Myth Busting: Long Term Use of Face Mask Cause Lung Cancer
The health officials all around the world encourage people to wear masks to slow down the spread of COVID 19 but according to a Facebook post, it claims that masks can give…
NICE Recommends Keytruda Plus Chemo for NSCLC Treatment
National Institute for Health and Care Excellence (NICE) has recommended Keytruda, alongside a combination of pemetrexed and platinum chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC). This combination is recommended…
Amgen Drug, Sotorasib, Shows Success in Phase II Trial against Non-Small Cell Lung Cancer
An Amgen Inc. lung cancer drug, sotorasib, targets an aggressive genetic mutation called KRAS. In the Phase II trial, this drug has shown to provide durable clinical benefit with pretreated non-small cell…
Study Shows Women Have Lower Risk of Death after Lung Cancer Surgery
The survival rates among men and women with lung cancer vary. Researchers at Karolinska Institutet in Sweden have conducted a study to find out the potential reasons behind these differences such as…
ACCC Releases Lung Cancer Care Quality Improvement Model
Lung Cancer is the second most common form of cancer among both men and women. Non-small cell lung cancer accounts for about 84% of lung cancer while small cell lung cancer cases…
Advances in Lung Cancer Treatment Reduce Death Rates
The leading cause of death in the United States remains lung cancer. The American Cancer Society estimates that almost 230,000 new lung cancer cases will be diagnosed in the country. The good…